Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1019, Issue , 2016, Pages 15-20

  Suneetha, A ^a   Raja Rajeswari, K ^b  

^a HINDU COLLEGE OF PHARMACY   (India)

^b ACHARYA NAGARJUNA UNIVERSITY   (India)

Author keywords

Dimethyl fumarate; Multiple sclerosis; Oxidative stress

Indexed keywords

COMMERCE; DIAGNOSIS; DISEASES; FREE RADICALS; OXIDATIVE STRESS; PATIENT MONITORING; RISK ASSESSMENT; SAFETY ENGINEERING; SCREENING; TISSUE;

BIOLOGICAL SAMPLES; CHRONIC INFLAMMATORY DISEASE; CLINICAL EXPERIENCE; DIMETHYL FUMARATE; INTRACELLULAR ACCUMULATION; MITIGATION STRATEGY; MULTIPLE SCLEROSIS; OXIDATIVE PATHWAYS;

PATIENT TREATMENT;

FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; TERIFLUNOMIDE; TRANSCRIPTION FACTOR NRF2;

ARTICLE; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; HUMAN; KIDNEY CANCER; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RELAPSE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM;

CLINICAL TRIALS AS TOPIC; DIMETHYL FUMARATE; HUMANS; MULTIPLE SCLEROSIS; OXIDATIVE STRESS;

EID: 84969348297     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2016.02.010     Document Type: Article

References (95)

1. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938.
2. Compston A., Coles A. Multiple sclerosis. Lancet. 2008, 372:1502.
3. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121.
4. Hafler D.A., Compston A., Sawcer S., et al. International multiple sclerosis genetics consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357:851.
5. Huynh J.L., Casaccia P. Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment. Lancet Neurol. 2013, 12:195.
6. Gh Popescu B.F., Lucchinetti C.F. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol. 2012, 12. article 11.
7. Lassmann H. Mechanisms of neuro degeneration shared between multiple sclerosis and Alzheimer's disease. J. Neural Transm. 2011, 118:747.
8. Centonze D., Muzio L., Rossi S., et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 2009, 29:3442.
9. Campbell G., Mahad D. Clonal expansion of mitochondrial DNA deletions and the progression of multiple sclerosis. CNS Neurol. Disord. Drug Targets 2012, 11:589.
10. Centonze D., Muzio L., Rossi S., Furlan R., Bernardi G., Martino G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ. 2010, 17:1083.
11. Kidd P.M. Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Altern. Med. Rev. 2005, 10:268.
12. Witte M., Nijland P., Drexhage J., et al. Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol. (Berl.) 2013, 125:231.
13. Blokhin A., Vyshkina T., Komoly S., Kalman B. Variations in mitochondrial DNA copy numbers in MS brains. J. Mol. Neurosci. 2008, 35:283.
14. Fischer M.T., Sharma R., Lim J.L., et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012, 135:886.
15. Tasset I., Aguera E., Sanchez-Lopez F., et al. Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin. Biochem. 2012, 45:440.
16. Nikic I., Merkler D., Sorbara C., et al. A reversible formof axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 2011, 17:495.
17. Oliveira S., Kallaur A., Simao A., et al. Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J. Neurol. Sci. 2012, 321:49.
18. Kalman B., Laitinen K., Komoly S. The involvement of mitochondria in the pathogenesis ofmultiple sclerosis. J. Neuroimmunol. 2007, 188:1.
19. Song Y., Pinniger G.J., Bakker A.J., et al. Lipopolysaccharide induced weakness in the preterm diaphragmis associated with mitochondrial electron transport chain dysfunction and oxidative stress. PLoS One 2013, 8:734.
20. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 2004, 251:261.
21. Poyton R.O., Ball K.A., Castello P.R. Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol. Metab. 2009, 20:332.
22. Surace M., Block M. Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cell. Mol. Life Sci. 2012, 69:2409.
23. Leto T.L., Geiszt M. Role of Nox family NADPH oxidases in host defense. Antioxid. Redox Signal. 2006, 8:1549.
24. Honorat J.A., Kinoshita M., Okuno T., et al. Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. PLoS One 2013, 8:713.
25. Ortiz G.G., Pacheco-Moises F.P., Bitzer-Quintero O.K., et al. Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin. Dev. Immunol. 2013, 708659.
26. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 2010, 49:1603.
27. Acar A., Ugur C.M., Evliyaoglu O., et al. Evaluation of serum oxidant/antioxidant balance in multiple sclerosis. Acta Neurol. Belg. 2012, 112:275.
28. Ghabaee M., Jabedari B., Al-E-Eshagh N., Ghaffarpour M., Asadi F. Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in GuillainBarre syndrome and multiple sclerosis patients. Int. J. Neurosci. 2010, 120:301.
29. Lassman H., Bruck W., Lucchinetti C. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17:210.
30. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247.
31. Lassman H., Horssen J.V., Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 2012, 8:647.
32. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 2004, 251:261.
33. Bjartmar C., Trapp B.D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 2001, 14:271.
34. Sayre L.M., Perry G., Smith M.A. Oxidative stress and neurotoxicity. Chem. Res. Toxicol. 2008, 21:172.
35. Montine K.S., Quinn J.F., Zhang J., et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem. Phys. Lipids 2004, 128:117.
36. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., Roberts L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:9383.
37. Mir F., Sadiq S. Elevated cerebrospinal fluid levels of an isoprostane, an oxidative stress biomarker in MS patients. Mult. Scler. J. 2011, 17:S53.
38. Fam S.S., Morrow J.D. The isoprostanes: unique products of arachidonic acid oxidation-a review. Curr. Med. Chem. 2003, 10:1723.
39. Milne G.L., Yin H., Brooks J.D., Sanchez S., Roberts L.J., Morrow J.D. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol. 2007, 433:113.
40. Milne G.L., Sanchez S.C., Musiek E.S., Morrow J.D. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat. Protoc. 2007, 2:221.
41. Pratico D., Rokach J., Lawson J., Fitzgerald G.A. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem. Phys. Lipids 2004, 128:165.
42. Oliveira S.R., Kallaur A.P., Reiche E.M. Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J. Neurol. Sci. 2012, 321:49.
43. Miller E., Mrowicka M., Saluk-Juszczak J., Ireneusz M. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem. Res. 2011, 36:1012.
44. Teunissen C.E., Sombekke M., Pratico D. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Mult. Scler. 2012, 18:1092.
45. Greco A., Minghetti L., Sette G., Fieschi C., Levi G. Cerebrospinal fluid isoprostanes show oxidative stress in patients with multiple sclerosis. Neurology 1999, 53:1876.
46. Mattsson N., Haghighi S., Andersen O., et al. Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci. Lett. 2007, 414:233.
47. Sbardella E., Greco A., Pozzilli C. Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Mult. Scler. 2013, 19:411.
48. Greco A., Minghetti L., Puopolo M., et al. Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 2004, 224:23.
49. Mir F., Lee D., Ray H., Sadiq S.A. CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflammation 2014, 1:21.
50. Center for Drug Evaluation and Research New Dug Application # 204063Orig1s000: Clinical Pharmacology and Biopharmaceutics Review, Reference ID: 3123618, US Food and Drug Administration, Rockville, MD. (Dated 29.4.12).
51. Nrf2 nuclear factor, erythroid 2-like 2 [Homo sapiens (human)] Gene ID: 4780, updated on 29-Sep-2013. Genes & Expression Database [Internet]. National Center for Biotechnology Information. Available from: (Last accessed 10.5.13). http://www.ncbi.nlm.nih.gov/gene/4780.
52. Nguyen T., Nioi P., Pickett C.B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 2009, 284:13291.
53. Shen H., Zhou S., Wang J. The paradoxical role of Nrf2 in tumor biology. Crit. Rev. Eukaryot. Gene Expr. 2013, 23:37.
54. Center for Drug Evaluation and Research New Dug Application # 204063 Orig1s000: Medical Review(s), Reference ID: 3214416, US Food and Drug Administration, Rockville, MD. Dated 3/25/13, Available from: (Last accessed 10.5.13). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000TOC.cfm.
55. Albrecht P., Bouchachia I., Goebels N., et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J. Neuroinflammation 2012, 9:163.
56. Wilms H., Sievers J., Rickert U., et al. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide IL-1ß, TNF-α and IL-6 in an in-vitro model of brain inflammation. J. Neuroinflammation 2010, 7:30.
57. Vandermeeren M., Janssens S., Wouters H., et al. Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. J. Invest. Dermatol. 2001, 116:124.
58. Treumer F., Zhu K., Glaser R., et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest. Dermatol. 2003, 121:1383.
59. Linker R.A., Lee D.H., Ryan S., et al. Fumaric acid esters exert neuroprotective effects in neuro inflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678.
60. Lin S.X., Lisi L., Russo Dello C., et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 2011, 3:75.
61. Gold R., Kappos L., Arnold D.L., et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis [DEFINE]. N. Engl. J. Med. 2012, 367:1098.
62. Fox R.J., Miller D.H., Phillips J.T., et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis [CONFIRM]. N. Engl. J. Med. 2012, 367:1087.
63. Long-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple Sclerosis Identifier: NCT00835770, database. US National Institutes of Health. Available from , (Last accessed 10.5.13). http://clinicaltrials.gov/ct2/show/NCT00835770%3Fterm=bg-12%26rank=6.
64. Juurlink B.H.J. Management of oxidative stress in the CNS: the many roles of glutathione. Neurotox. Res. 1999, 1:119.
65. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 2004, 251:261.
66. Syburra C., Passi S. Oxidative stress in patients with multiple sclerosis. Ukr. Biokhim. Zh. 1999, 71:112.
67. Riise T., Nortvedt M.W., Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 2003, 61:1122.
68. Morini M., Roccatagliata L., Dell'Eva R., et al. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 148:146.
69. Liu B., et al. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 2003, 139:27.
70. Hendriks J.J., De Vries H.E., Van der Pol S.M., Van den Berg T.K., Van Tol E.A., Dijkstra C.D. Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study. Biochem. Pharmacol. 2003, 65:877.
71. Gonsette R.E. Neurodegeneration in multiple sclerosis: the role of oxidatvie stress and excitotoxicity. J. Neurol. Sci. 2008, 274:48.
72. Sayre L.M., Perry G., Smith M.A. Oxidative stress and neurotoxicity. Chem. Res. Toxicol. 2008, 21:172.
73. Besler H.T., Comoglu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr. Neurosci. 2003, 6:189.
74. Miller E., Mrowicka M., Saluk-Juszczak J., Majsterek I. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem. Res. 2011, 36:1012.
75. Frei B., Stocker R., Ames B.N. Antioxidant defences and lipid peroxidation in human blood plasma. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:9748.
76. Miller E., Walczak A., Saluk J., Ponczek M.B., Majsterek I. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clin. Biochem. 2012, 45:26.
77. Stefan L., Terezia K., Jana M. Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis. Health 2013, 5:1924.
78. Arundhati J., Kalipada P. Oxidative stress kills human primary Oligodendrocytes via neutral sphingomyelinase: implications for multiple sclerosis. J. Neuroimmune Pharmacol. 2007, 2:184.
79. Linker R.A., Lee D.H., Ryan S., Van Dam A.M., Conrad R., Bista P., Zeng W., Hronowsky X., Buko A., Chollate S., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678.
80. Schmidt M.M., Dringen R. Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem. Int. 2010, 57:460.
81. Scannevin R.H., Chollate S., Jung M.Y., et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. 2012, 341:274.
82. Albrecht P., Bouchachia I., Zimmermann C., et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J. Neuroinflammation 2012, 9:163.
83. Rachakonda G., Xiong Y., Sekhar K.R., Stamer S.L., Liebler D.C., Freeman M.L. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem. Res. Toxicol. 2008, 21:705.
84. Bogdanov M.B., Andreassen O.A., Dedeoglu A., Ferrante R.J., Beal M.F. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 2001, 79:1246.
85. Kappos L., Gold R., Miller D.H., et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult. Scler. 2012, 18:314.
86. Bittner S., Meuth S.G., Gobel K., et al. TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain 2009, 132:2501.
87. Ashrafian H., Czibik G., Bellahcene M., et al. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab. 2012, 15:361.
88. Lamas J.P., Sanchez-Prado L., Regueiro J., Llompart Garcia-Jares M.C. Determination of dimethyl fumarate and other potential allergens in desiccant and antimould sachets. Anal. Bioanal. Chem. 2009, 394:2231.
89. Liu S., Su K. Determination of antimicrobial preservative dimethyl fumarate by high performance liquid chromatography. Se Pu 1998, 16:180.
90. HuiWen H., FeiFei H., JiaYin Z., YaBin H., JianJun W. Determination of dimethyl fumarate in food by high performance liquid chromatography. Acta Agric. Shanghai 2009, 25:72.
91. Narizzano R., Risso F., Venturelli G., Devia C., Carlini E., Maggiolo S. Gas chromatography-mass spectrometry analysis of dimethyl fumarate in consumer products. J. Chromatogr. A 2009, 1216:6762.
92. Patrizia S., Danilo A.B., Silvana G., Angela S., Roberto D. Determination of dimethyl fumarate (DMFu) in silica gel pouches using gas chromatography coupled ion trap mass spectrometry. J. Environ. Sci. Health B 2011, 46:341.
93. Tsuyoshi K., Kazuo I., Atsuko M., Tetsuji N. Determination of dimethyl fumarate and other fumaric and maleic acid diesters in desiccants and consumer products in Japan. J. Health Sci. 2011, 57:236.
94. Oriella G., Domenico M., Antonio S., Stefania A., Lucia G. Determination of dimethyl fumarate in desiccant and antimould sachets by reversed-phase liquid chromatography. Biomed. Chromatogr. 2011, 25:1315.
95. Donghua Z., Geoff G.Z.Z., Laren L.S.T.G., Deliang Z. A Noel accelerated oxidative stability screening method for pharmaceutical solids. J. Pharm. Sci. 2011, 10.1002/jps.22580.